| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3385463 | Revista Colombiana de Reumatología | 2014 | 13 Pages |
Abstract
Patients treated with MF, tacrolimus and CY have similar rates of remission; however there is greater benefit in outcome response when comparing tacrolimus and CY. Comparing MF with CY showed a lower risk of menstrual abnormalities and reduced risk of alopecia.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Hugo Alberto Páez Ardila, Libardo Enrique Lobato Suárez, Viviana Alejandra RodrÃguez, Gerardo Quintana L.,